By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BD Diagnostics and Bruker Daltonics jointly announced today a co-development and co-marketing agreement for microbial identification technologies.

The firms said that they will promote an emerging, integrated approach to bacterial and fungal identification and antimicrobial susceptibility testing through a combination of their technologies. The collaboration will combine Bruker's MALDI Biotyper microbial identification system with BD's Phoenix Microbiology System.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.